ArticleThe Journal of allergy and clinical immunology2023
Local type 2 immunity in eosinophilic gastritis.
Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2026Trial
- Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.The lancet. Gastroenterology & hepatology · 2023Trial
- Article
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- [Research progress on risk factors for poor prognosis in pediatric non-esophageal eosinophilic gastrointestinal disorder].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Segmental overlap is common in eosinophilic gastrointestinal diseases and impacts clinical presentation and treatment.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Age-Dependent Clinical Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.Journal of asthma and allergy · 2025Article
- Machine learning-based identification and characterization of mast cells in eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2024Article
- Eosinophilic gastroenteritis with hemorrhagic ascites: a case report.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEosinophilic gastritis (EoG) associates with type 2 immunity. However, the type 2 cytokine cellular source, gastric T-cell composition, and gastric T-cell relationship (or relationships) with disease pathology remain understudied.
objectiveWe defined gastric T-cell populations and their association with histologic and endoscopic EoG pathology.
methodsGastric biopsy samples (n = 6 EoG, n = 7 control) were subjected to histologic, endoscopic, and flow cytometry analyses. In a complementary cohort (n = 83 EoG), IL4, IL5, and IL13 mRNA levels were correlated with EoG pathologic parameters.
resultsGastric biopsy samples contained CD3
conclusionsEoG is a T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.